Patents by Inventor Lawrence Tamarkin
Lawrence Tamarkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150018486Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, the nanotherapeutic compositions of the present invention comprise a platform comprising a colloidal metal, a targeting ligand such a tumor necrosis factor, a stealth agent such as polyethylene glycol, and one or more diagnostic or therapeutic agents for delivery. The invention also comprises methods and compositions for making such nanotherapeutic compositions and for the treatment of cancer.Type: ApplicationFiled: February 14, 2014Publication date: January 15, 2015Applicant: Cytlmmune Sciences, Inc.Inventors: Lawrence Tamarkin, Giulio F. Paciotti, Marja S. Huhta
-
Publication number: 20140220133Abstract: A composition and methods to bind and remove toxic agents from a subject exposed to the toxic agents are described herein. The composition comprises a stealth agent and scavenging agent bound to a nanoparticle platform. The stealth agent prevents the nanomedicine from detection and elimination by the immune system allowing the scavenging agent to bind the target toxic agent. The stealth agent comprises an exposing group that once removed from the stealth agent allows the nanomedicine and bound toxic agent to be detected and eliminated from the subject's body.Type: ApplicationFiled: November 27, 2013Publication date: August 7, 2014Inventors: Giulio F. Paciotti, Lawrence Tamarkin
-
Patent number: 8785202Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.Type: GrantFiled: February 18, 2010Date of Patent: July 22, 2014Assignee: CytImmune Sciences, Inc.Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Patent number: 8486663Abstract: The compositions and methods of the present invention comprise the efficient and effective presentation of antigens to the appropriate components of the immune system resulting in the production of species-specific antibodies in vitro. In general, these compositions comprise one or more antigenic components together with a colloidal metal, optionally combined with derivatized PEG (polyethylene glycol) or other agents. The invention also comprises methods and compositions for making such colloidal metal compositions.Type: GrantFiled: May 12, 2011Date of Patent: July 16, 2013Assignee: Cytlmmune Sciences, Inc.Inventors: Giulio F. Paciotti, Ramadevi Raghunandan, Marja S. Huhta, Lawrence Tamarkin
-
Patent number: 8435801Abstract: The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells.Type: GrantFiled: April 20, 2011Date of Patent: May 7, 2013Assignee: Cytimmune Sciences, Inc.Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Publication number: 20120134956Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.Type: ApplicationFiled: October 26, 2011Publication date: May 31, 2012Applicant: CYTIMMUNE SCIENCES, INC.Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Patent number: 8137989Abstract: In accordance with the present invention, a composition and method is provided that allows for the administration of a biologically-active factors to a human or animal. The present invention can be used to treat a disease with a biologically-active factor or combination of biologically-active factors, or can be used to safely vaccinate a human or animal against a biologically-active factor. It can also be used as a method for the delivery of biologically-active factors for the treatment of disease. Additionally, the present invention also includes a method of targeted drug delivery for the treatment of disease through the administration of custom complexes containing of one or more biologically active factors bound to a colloidal metal where at least one of the biologically-active factors is capable of binding a high affinity receptor on a cell surface.Type: GrantFiled: September 26, 2003Date of Patent: March 20, 2012Assignee: CytImmune Sciences, Inc.Inventors: Lawrence Tamarkin, Giulio Paciotti
-
Publication number: 20110275123Abstract: The compositions and methods of the present invention comprise the efficient and effective presentation of antigens to the appropriate components of the immune system resulting in the production of species-specific antibodies in vitro. In general, these compositions comprise one or more antigenic components together with a colloidal metal, optionally combined with derivatized PEG (polyethylene glycol) or other agents. The invention also comprises methods and compositions for making such colloidal metal compositions.Type: ApplicationFiled: May 12, 2011Publication date: November 10, 2011Inventors: Giulio F. Paciotti, Ramadevi Raghunandan, Marja S. Huhta, Lawrence Tamarkin
-
Publication number: 20110195456Abstract: The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells.Type: ApplicationFiled: April 20, 2011Publication date: August 11, 2011Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Patent number: 7960145Abstract: The compositions and methods of the present invention comprise the efficient and effective presentation of antigens to the appropriate components of the immune system resulting in the production of species-specific antibodies in vitro. In general, these compositions comprise one or more antigenic components together with a colloidal metal, optionally combined with derivatized PEG (polyethylene glycol) or other agents. The invention also comprises novel cytokine cocktails for generating desired antibodies.Type: GrantFiled: November 10, 2008Date of Patent: June 14, 2011Assignee: CytImmune Sciences, Inc.Inventors: Giulio F. Paciotti, Ramadevi Raghunandan, Marja S. Huhta, Lawrence Tamarkin
-
Patent number: 7951614Abstract: The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells.Type: GrantFiled: August 27, 2009Date of Patent: May 31, 2011Assignee: CytImmune Sciences, Inc.Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Publication number: 20110014118Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, the nanotherapeutic compositions of the present invention comprise a platform comprising a colloidal metal, a targeting ligand such a tumor necrosis factor, a stealth agent such as polyethylene glycol, and one or more diagnostic or therapeutic agents for delivery. The invention also comprises methods and compositions for making such nanotherapeutic compositions and for the treatment of cancer.Type: ApplicationFiled: July 26, 2010Publication date: January 20, 2011Inventors: Lawrence Tamarkin, Giulio F. Pacciotti, Marja S. Huhta
-
Patent number: 7790167Abstract: The methods and compositions of the present invention are directed to enhancing an immune response and increasing vaccine efficacy through the simultaneous or sequential targeting of specific immune system components. More particularly, specific immune components, such as macrophages, dendritic cells, B cells and T cells, are individually activated by component-specific immunostimulating agents. One such component-specific immunostimulating agent is an antigen-specific, species-specific monoclonal antibody. The invention is also directed to a method for the in vitro production of the antigen-specific, species-specific monoclonal antibodies which relies upon the in vitro conversion of blood-borne immune cells, such as macrophages and lymphocytes. Vaccine efficacy is enhanced by the administration of compositions containing component-specific immunostimulating agents and other elements, such as antigens or carrier particles, such as colloidal methods, such as gold.Type: GrantFiled: December 19, 2002Date of Patent: September 7, 2010Assignee: Cyt Immune Sciences, Inc.Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Publication number: 20100143298Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.Type: ApplicationFiled: February 18, 2010Publication date: June 10, 2010Inventors: LAWRENCE TAMARKIN, Giulio F. Paciotti
-
Publication number: 20100068261Abstract: The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells.Type: ApplicationFiled: August 27, 2009Publication date: March 18, 2010Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Publication number: 20090148908Abstract: The compositions and methods of the present invention comprise the efficient and effective presentation of antigens to the appropriate components of the immune system resulting in the production of species-specific antibodies in vitro. In general, these compositions comprise one or more antigenic components together with a colloidal metal, optionally combined with derivatized PEG (polyethylene glycol) or other agents. The invention also comprises novel cytokine cocktails for generating desired antibodies.Type: ApplicationFiled: November 10, 2008Publication date: June 11, 2009Inventors: Giulio F. PACIOTTI, Ramadevi Raghunandan, Marja S. Huhta, Lawrence Tamarkin
-
Publication number: 20090104114Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, the nanotherapeutic compositions of the present invention comprise a platform comprising a colloidal metal, a targeting ligand such a tumor necrosis factor, a stealth agent such as polyethylene glycol, and one or more diagnostic or therapeutic agents for delivery. The invention also comprises methods and compositions for making such nanotherapeutic compositions and for the treatment of cancer.Type: ApplicationFiled: September 22, 2008Publication date: April 23, 2009Applicant: CytImmune Sciences, Inc.Inventors: Lawrence Tamarkin, Giulio F. Paciotti, Marja S. Huhta
-
Publication number: 20090035265Abstract: The present invention relates to compositions and methods for targeted delivery of biologically-active factors, such as cytokines, growth factors, chemotherapeutic agents, nucleic acids, and therapeutic agents. The compositions of the present invention can be used to treat diseases and pathologies in organisms. Additionally the invention relates to methods and compositions for the enhancement of an immune response in a human or animal. Such enhancement may result in stimulation or suppression of the immune response. Other compositions and methods of the present invention include vaccines and those used for reduction of the toxicity of agents.Type: ApplicationFiled: October 13, 2008Publication date: February 5, 2009Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Patent number: 7387900Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.Type: GrantFiled: April 30, 2002Date of Patent: June 17, 2008Assignee: Cytimmune Sciences, Inc.Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Patent number: RE42524Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.Type: GrantFiled: October 24, 2007Date of Patent: July 5, 2011Assignee: Cytimmune Sciences, Inc.Inventors: Lawrence Tamarkin, Giulio F. Paciotti